Latha Radhakrishnan, MD
Endocrinology, Diabetes & Metabolism · Portland, ORNPI 1598787426
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.
Across 42 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$189
- Medtronic$156
- Organon$84
- Amgen$67
- Apellis Pharmaceuticals, Inc.$60
- Tandem Diabetes Care, Inc.$58
- plus $297 from 12 others
What the payments were for
- Food & beverage$88797%
- Education$243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $189 |
| Medtronic(2 entities) | 7 | $156 |
| Organon | 2 | $84 |
| Amgen(2 entities) | 3 | $67 |
| Apellis Pharmaceuticals, Inc. | 1 | $60 |
| Tandem Diabetes Care, Inc. | 2 | $58 |
| Abbott | 3 | $51 |
| Lilly USA, LLC | 2 | $42 |
| Dexcom, Inc. | 2 | $37 |
| AstraZeneca | 2 | $35 |
| BETA Bionics, Inc. | 1 | $24 |
| AbbVie | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Corcept Therapeutics | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$911 in reported general payments places this provider in the 55th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 180 | $204,312 |
| JardianceEmpagliflozin | 78 | $79,769 |
| TrulicityDulaglutide | 52 | $56,246 |
| MounjaroTirzepatide | 46 | $54,491 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $22,091 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $10,910 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 25 | $6,646 |
| BaqsimiGlucagon | 18 | $5,979 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $4,602 |
| Admelog SolostarInsulin Lispro | 17 | $4,142 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,950 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 22 | $2,399 |
| Insulin Lispro | 11 | $1,464 |
| SynthroidLevothyroxine Sodium | 12 | $1,205 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 11 | $859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $189 | $204,312180 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Baqsimi, Insulin Lispro | $42 | $118,180127 claims |
| AbbVieSynthroid | $19 | $1,20512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Portland
- Michael McClungPortland$1.3M
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
- Eric OrwollPortland$94K
- Paul DuellPortland$91K
- Sergio FazioPortland$88K
- Nancy CuroshPortland$59K
- Andrew AhmannPortland$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.